Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990)
Hong Kong
· Delayed Price · Currency is HKD
161.50
-4.10 (-2.48%)
Nov 15, 2024, 9:30 AM HKT
Sichuan Kelun-Biotech Biopharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 1,877 | 1,540 | 803.93 | 32.32 |
| Revenue Growth (YoY) | 24.71% | 91.62% | 2387.26% | - |
| Cost of Revenue | 713.66 | 751.64 | 277.14 | 23.07 |
| Gross Profit | 1,163 | 788.85 | 526.8 | 9.25 |
| Selling, General & Admin | 217.04 | 199 | 93.03 | 90.98 |
| Research & Development | 1,193 | 1,031 | 845.98 | 727.67 |
| Other Operating Expenses | -62.95 | 12.59 | -18.27 | -14.16 |
| Operating Expenses | 1,347 | 1,243 | 920.75 | 804.49 |
| Operating Income | -183.64 | -453.7 | -393.95 | -795.24 |
| Interest Expense | -8.08 | -84.31 | -148.81 | -112.59 |
| Interest & Investment Income | 49.6 | 45.19 | 1.42 | 0.81 |
| Currency Exchange Gain (Loss) | 28.83 | 16.09 | -31.94 | 16.88 |
| EBT Excluding Unusual Items | -113.3 | -476.74 | -573.3 | -890.15 |
| Gain (Loss) on Sale of Investments | 14.29 | 10.53 | 0.51 | 0.36 |
| Gain (Loss) on Sale of Assets | -0.72 | -1.49 | 5.42 | -0.01 |
| Pretax Income | -99.72 | -467.69 | -567.36 | -889.8 |
| Income Tax Expense | 133.06 | 106.44 | 48.74 | - |
| Net Income | -232.78 | -574.13 | -616.1 | -889.8 |
| Preferred Dividends & Other Adjustments | -46.17 | -51.93 | -68 | -67.25 |
| Net Income to Common | -186.61 | -522.21 | -548.1 | -822.55 |
| Shares Outstanding (Basic) | 218 | 184 | 96 | 92 |
| Shares Outstanding (Diluted) | 218 | 184 | 96 | 92 |
| Shares Change (YoY) | 75.62% | 92.24% | 3.31% | - |
| EPS (Basic) | -0.86 | -2.84 | -5.74 | -8.90 |
| EPS (Diluted) | -0.86 | -2.84 | -5.74 | -8.90 |
| Free Cash Flow | -564.5 | -21.42 | -304.51 | -580.03 |
| Free Cash Flow Per Share | -2.59 | -0.12 | -3.19 | -6.27 |
| Gross Margin | 61.98% | 51.21% | 65.53% | 28.62% |
| Operating Margin | -9.78% | -29.45% | -49.00% | -2460.37% |
| Profit Margin | -9.94% | -33.90% | -68.18% | -2544.86% |
| Free Cash Flow Margin | -30.07% | -1.39% | -37.88% | -1794.52% |
| EBITDA | -142.39 | -419.78 | -367.99 | -775.61 |
| EBITDA Margin | -7.59% | -27.25% | -45.77% | - |
| D&A For EBITDA | 41.26 | 33.92 | 25.97 | 19.63 |
| EBIT | -183.64 | -453.7 | -393.95 | -795.24 |
| EBIT Margin | -9.78% | -29.45% | -49.00% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.